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Abstract: Emerging evidence suggests that disordered eating, particularly binge-eating
symptomatology, is overrepresented within Polycystic Ovary Syndrome (PCOS) populations.
This comorbidity presents a clinical dilemma as current treatment approaches for PCOS
emphasize the importance of weight management, diet, exercise, and the potential for harm
of such treatment approaches in PCOS patients with comorbid disordered eating. However,
limited research has assessed the occurrence of binge eating and disordered eating in PCOS
patients. Consequently, little is known about the prevalence of binge eating in PCOS, and the
possible etiological processes to explain this comorbidity remain poorly understood. Given
the paucity of research on this topic, the aims of this narrative review are fourfold: 1) to
outline the main symptoms of PCOS and binge eating; 2) to provide an overview of the
prevalence of binge eating in PCOS; 3) to outline possible etiological factors for the
comorbidity between PCOS and binge eating; and 4) to provide an overview of management
strategies of binge eating in PCOS.
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Introduction
Polycystic Ovary Syndrome (PCOS) is the most common endocrine condition in
women of reproductive age, occurring in approximately 15–20% of the women.1,2
PCOS is diagnosed by the presence of 2 of 3 the following criteria: high levels of
androgens (male sex hormones), missed or irregular periods, and various small
cysts (ﬂuid-ﬁlled sacs in the ovaries).3 Many established comorbidities have been
associated with PCOS including an increased risk for obesity, type II diabetes,
cardiovascular diseases,4 infertility5 and mental disorders such as anxiety,
depression,6 and eating disorders (EDs).7 EDs characterized by binge eating beha-
viors, such as bulimia nervosa (BN) and binge eating disorder (BED) appear to be
the most prevalent disorders within PCOS populations; suggesting that binge-eating
symptomatology may be particularly relevant within this population.7 However, to
date, relatively few studies8 have assessed the occurrence of binge eating in PCOS
patients. Consequently, little is known about the prevalence of binge eating in
PCOS, and the etiological processes to account for this comorbidity. This is
particularly important given that current treatment guidelines for PCOS emphasize
the importance of weight management, dietary interventions, and physical activity,
in the management of PCOS and the potential for harm of such treatment
approaches for individuals with comorbid disordered eating.9 Furthermore,
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formalized treatment guidelines which address both pro-
blem sets simultaneously are currently lacking. Therefore,
the aims of the current review are fourfold: 1) to outline
the main symptoms of PCOS and binge eating; 2) to
provide an overview of the prevalence of binge eating in
PCOS; 3) to outline possible etiological factors for the
comorbidity between PCOS and binge eating; and 4) to
provide an overview of management strategies of binge
eating in PCOS.
The main features of PCOS
Many of the clinical features of PCOS are caused by high
levels of androgens resulting in hyperandrogenism.1
Hyperandrogenism can lead to many adverse effects in
women with this condition, including the growth of ovar-
ian cysts, weight gain, hair growth, especially increased
body and facial hair (hirsutism), acne, and hair loss (alo-
pecia) in the central part of the scalp.10,11 High levels of
androgens affect menstruation and ovulation, and women
with PCOS commonly suffer from menstrual irregularities,
especially oligomenorrhea (infrequent bleeding), or ame-
norrhea (no menstrual period) and oligoovulation (infre-
quent ovulation) or anovulation (absent ovulation).2
Additionally, PCOS women present with a range of meta-
bolic features including insulin resistance, type 2 diabetes,
and cardiovascular risk factors, and subsequently PCOS is
associated with a greater risk of being overweight or
obese.12,13 Obesity is known to exacerbate all metabolic
and reproductive outcomes for women with PCOS, as well
as anxiety and depressive symptoms.6,14,15
As a chronic disease associated with complex physical
and body image related challenges, PCOS is associated
with decreased health-related quality of life and emotional
well-being.16 Additionally, insulin resistance is generally
followed by intense carbohydrate cravings, which may
promote overeating.11 These factors have been strongly
associated with the development of psychiatric illnesses
including depression, anxiety, and EDs, especially those
EDs characterized by binge eating symptomatology.17–19
EDs characterized by binge eating
behavior
Binge eating behavior is characterized by 1) eating, in
a discrete period of time (eg, within any 2-hr period), an
amount of food that is deﬁnitely larger than what most
people would eat in a similar period of time under similar
circumstances; and 2) the binge episode is accompanied by
a loss of control over eating (eg, a feeling that one cannot
stop eating or control what or how much one is eating).20
Various types of EDs, such as BN, Anorexia Nervosa
Binge Purging type (AN-BP), BED, and other speciﬁed
feeding or eating isorder (OSFED) and unspeciﬁed feeding
eating or disorder, may be characterized by binge eating
behaviors.20 BN is estimated to have a prevalence of
approximately 1–1.5% in young adult women. Its main
features include recurrent episodes of binges, and compen-
satory behaviors such as purging behavior, excessive exer-
cise, and/or dieting, which individuals employ to control
their shape and weight.20 AN-BP is characterized by the
same binge-purging criteria as BN, but individuals experi-
encing this ED diagnosis generally present with a lower
body mass index (BMI, <18.5 kg/m2). Its prevalence esti-
mates are lower than BN, with an estimated occurrence of
0.4%.20
Unlike those with BN and AN-BP, individuals with
BED do not use compensatory behaviors, such as self-
induced vomiting or over-exercising following binge eat-
ing episodes. BED is therefore exclusively characterized
by binge eating episodes. It is more common than BN and
AN-BP, with an estimated prevalence of 1.6% in the gen-
eral population.20 Most individuals with BED are over-
weight or obese and approximately 50% of the people
diagnosed with BED are clinically obese.21 Finally,
OSFED may present with many of the symptoms such as
AN-BP, BN, or BED, but individuals diagnosed with this
disorder do not fulﬁll the diagnostic criteria for these ED
diagnoses. Currently, the DSM-520 outlines ﬁve different
types of OSFED, which include: atypical AN, BN (of low
frequency and/or limited duration), BED (of low fre-
quency and/or limited duration), purging disorder, and
night eating syndrome. OSFED is the most common ED
diagnosis, and it is estimated that around 30% of the
people, who seek treatment for an ED have OSFED.
However, there are currently only very few prevalence
studies of OSFED, mainly because of the difﬁculties in
capturing its heterogeneous nature. The few studies
reported in the literature have so far shown a prevalence
of OSFED of approximately 3–6% in community
samples.22
Binge eating is associated with difﬁculties managing
weight, including weight gain,23 obesity onset,24 and
unsuccessful attempts to lose weight.25 Binge eating has
also been associated with impaired physical health and
quality of life.26 Moreover, individuals with binge eating
often have impaired psychological functioning, including
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high rates of comorbid psychological disorders, such as
anxiety and depression,27 which as previously outlined, are
also common in women with PCOS women.8,19 Such
impairments in psychological function may be partially
attributed to the binge eating symptomatology, since indi-
viduals typically experience shame and distress as a result
of their eating patterns.28,29 EDs characterized by bingeing
symptoms, particularly BED, have been associated with
similar physical comorbidities evident in PCOS popula-
tions, including an increased risk of medical complications
associated with obesity, such as type II diabetes, cardio-
vascular disorders, and fertility issues.30,31 These ﬁndings
demonstrate signiﬁcant commonalities in psychological
and physical comorbidities present in individuals with
PCOS and binge eating behaviors.
Method for review
Despite research indicating that women with PCOS are
more likely to experience ED pathology, particularly binge
eating behaviors, a paucity of research has explored the
prevalence of these behaviors in women with PCOS.
A systematic review was not conducted to explore this
question, rather the literature was narratively reviewed
based on clinical expertise. In this narrative review, collated
research ﬁndings, which examined the presence of disor-
dered eating behaviors and/or ED diagnoses, in women with
PCOS are presented. We assembled relevant research ﬁnd-
ings without imposing speciﬁc inclusion/exclusion criteria
(eg, criteria for PCOS diagnosis, inclusion of a comparison
group, or ED assessment method). Subsequently, this
review extends existing literature, by including studies
beyond those only diagnosed using the PCOS Rotterdam
criteria.3 The Rotterdam criteria deﬁne PCOS by the pre-
sence of at least two out of three criteria: oligo-anovulation,
clinical, and/or biochemical hyperandrogenism and poly-
cystic ovaries (≥12 follicles measuring 2–9 mm in diameter
or ovarian volume 0.10 mL in at least one ovary).3 While
these criteria are endorsed in treatment guidelines for diag-
nosing PCOS in adults,32 the development of these criteria
was based on expert meetings and not on evidence-based
treatment guidance.33 Additionally, literature has shown that
overall the diagnosis of PCOS is difﬁcult, as the exhibiting
signs and symptoms are diverse, depending on the popula-
tions assessed, the degree of obesity, and life phase of the
women experiencing this disorder.32 Therefore, by broad-
ening our inclusion criteria, we aim to examine the relation-
ship between PCOS and binge eating behaviors within
diverse PCOS phenotype groups.
Prevalence of binge eating in PCOS
patients
The results of the narrative review are presented in Table 1.
Eight of the studies presented8,15,34–39 were included in
a recent meta-analysis,7 which assessed the increased like-
lihood of experiencing ED symptoms in PCOS populations
in comparison to healthy female controls. The authors of
this review performed a systematic review and meta-
analysis of studies that assessed women with well-deﬁned
PCOS, according to either contemporary Rotterdam
criteria3 or NIH criteria and controls without PCOS.
Furthermore, the selected studies employed validated ED
screening tools to assess abnormal ED scores and/or pre-
valence of speciﬁc ED diagnoses. Results8,15,34–39 included
470 women with PCOS and 390 controls, who met inclu-
sion criteria for the systematic review.
A meta-analysis on seven of these studies revealed that
women with PCOS had over three times the odds of having
abnormal ED scores (OR 3.05; 95%CI 1.33, 6.99 four stu-
dies) as well as being diagnosed with an ED (OR 3.87; 95%
CI 1.43, 10.49), when compared to women without PCOS.
However, there was not enough power to statistically assess
which exact ED subtype this increased risk was attributable
to. The authors did note though that the PCOS group revealed
a signiﬁcantly higher BMI than the control sample.20 This is
signiﬁcant as obese individuals with BED, and non-obese
BED groups differ in their drive for thinness, frequency of
objective binge eating episodes, and concern about
weight.40,41 Therefore, BMI differences are likely to inﬂu-
ence binge eating behaviors, and BMI differences rather than
PCOS status, may account for some variation in binge-eating
symptomatology. The remaining studies included in the nar-
rative review assessed ED behaviors in PCOS
women17,18,42–52 without imposing inclusion criteria (eg,
PCOS diagnosed according to Rotterdam criteria3 or NIH
criteria, controls without PCOS, and type of ED screening
tools). The studies examining clinically signiﬁcant disor-
dered eating symptoms reported a prevalence between
6.8% and 58% for binge eating symptoms,17,46,48,51 and
between 2.3% and 33.33%17,42,49 for BN symptoms. The
prevalence of a diagnosed ED varied between diagnostic
categories, for AN estimates, ranged between 0.0% and
1.3%,17,18,44,50 for BN between 0.0% and
12.6%,17,18,42,44,50 for BED between 4% and 15%,17,44,50,52
and one study reported a prevalence of 22.5% for EDNOS.50
Two studies43,47 assessed dietary patterns in women with
PCOS. Results showed that PCOS women had higher
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overall energy intake than national averages, consumed sig-
niﬁcantly more sweet than savory snacks, and that BMI was
negatively associated with eating frequency,. These ﬁndings
suggest that PCOS women’s overall energy intake is higher
than average, and is consumed in fewer episodes of eating.
The overall prevalence of any ED presented in the
current review ranged from 0% to 22.5%, while the pre-
valence of clinically signiﬁcant disordered eating was gen-
erally higher, ranging from 8.3% to 58%. This is
signiﬁcant, as many women will report disordered eating
symptoms, that are associated with distress and impair-
ment, which may not fulﬁll diagnostic criteria for
a speciﬁc ED diagnosis.53
Regarding the assessment of disordered eating symp-
toms, the studies included in the review varied considerably
in their assessment. The majority of these studies used self-
report questionnaires, such as the Eating Attitudes Test-2652
EAT55 eg,31,32) or the Bulimia Investigation Test56,
Edinburgh53 (BITE eg,30,45) to assess ED symptoms.
Studies which employed self-report measures to assess dis-
ordered eating3,8,30–33,37,40,44,45,49 reported clinically ele-
vated ED symptoms in women with PCOS.
While these studies provide evidence that ED symptoms
are elevated in PCOS populations, reliable inferences about
the prevalence and nature of ED diagnoses in this population
are difﬁcult to infer from self-report measures. Interview-
basedmethods for diagnosing EDs, such as the SCID57 or the
Eating Disorder Examination58, may be better placed to
reliably characterize the prevalence of EDs in women with
PCOS. However, these measures were only used in a small
proportion of the studies included (eg, 15,38,46,50).
Furthermore, several studies did not include a control group
(eg, 17,43,45–47,50). Most studies (eg, 17,38,48) used the PCOS
Rotterdam criteria to establish a diagnosis, while other stu-
dies used self-report measures to diagnose PCOS
(eg, 34,43,51), and only a few studies employed ultrasound to
establish a PCOS diagnosis (eg 42,44,49). There are also a few
studies (eg, 47,50,52) that did not provide any information on
how PCOS was assessed. Consequently, caution should be
exercised when interpreting the ﬁndings of these studies.
In summary, the results of the review demonstrate that
EDs, particularly those characterized by binge-eating, are
prevalent in PCOS populations, and that a signiﬁcant pro-
portion of women with PCOS report clinically signiﬁcant
disordered eating symptoms that may not necessarily meet
the threshold for an ED diagnosis. The variability in pre-
valence estimates of disordered eating in PCOS may be
attributable to the measures employed to assess disordered
eating. Diagnostic overshadowing of PCOS symptoms
may also impede a reliable diagnosis, and concealment
and shame of disordered eating symptoms, or the health
care professionals’ dearth of knowledge and skill sets in
identifying and treating ED symptoms may also contribute
to variable prevalence estimates.17,59
What are the connections between
PCOS and binge eating behavior?
Despite the association between PCOS and binge eating,
an etiological link has never been satisfactorily
explained.19 However, the development of binge eating
behavior among women with PCOS is unsurprising,
given the overlap in symptoms such as difﬁculty losing
weight, irregular menstrual cycles, infertility, and
hirsutism.1,19,34 The connections between PCOS and
binge eating are most likely numerous and complex. In
the subsequent paragraphs, we will, therefore, provide
a distinction between the most prominent metabolic, hor-
monal, and psychological factors, that may explain the
relationship between the two disorders.
Hormonal factors – hyperandrogenism
Research has found that hormonal and menstrual irregula-
rities confer vulnerability to both PCOS1,10,11 and binge
eating behavior.60,61 Androgens, including testosterone,
are present in both sexes, however, the levels are generally
lower in females than males. A prominent feature of PCOS
is elevated concentrations of testosterone, which account
for numerous of the PCOS related symptoms, including
hirsutism, acne, scalp hair loss, irregular menses, and
diminished fertility.9,11,62 Hyperandrogenism is implicated
in PCOS9 and binge eating behavior63,64 and has fre-
quently been linked to the causation of menstrual irregula-
rities, including amenorrhea, and a delay and/or lack of
ovulation.65,66 These menstrual irregularities may lead to
increased hunger and psychological distress, potentially
resulting in an increase in binge eating frequency.61,67
Another potential hypothesis for the relationship between
PCOS and binge eating behavior may be that hyperandro-
genism inﬂuences the occurrence of bulimic behavior. As
previously outlined, high androgen levels in women have
been found to stimulate appetite64,68 and increase anxious
and depressed mood states.69,70 Therefore, high androgen
levels may confer risk for binge eating behaviors, as binge
eating episodes often occur in an attempt to modulate nega-
tive affective states (such as anxious and depressed moods),
Krug et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Neuropsychiatric Disease and Treatment 2019:151280
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
or via impaired impulse control because of the
appetite-stimulating effects of high androgen levels. In agree-
ment with the assumption that androgens might trigger
binge-purging behavior, ﬁndings from a pilot study revealed
that the administration of androgen receptor antagonist ﬂu-
tamide leads to a substantial decrease in bulimic symptoms.71
Further research is required to provide further support for the
different hypotheses presented here.
Metabolic imbalances – insulin resistance
Most attempts to explain the relationship between PCOS
and ED symptomatology, especially binge eating, have
rested on the role of insulin.67 This has resulted in the
proposition of a hyperglycemia hypothesis. Insulin is an
important hormone that signals muscle, fat, and liver cells
to use glucose from the bloodstream for energy for the
body. Almost all women diagnosed with PCOS will have
high levels of insulin because of the development of per-
ipheral insulin resistance, which results in weight gain.
Insulin resistance is a strong risk factor for metabolic syn-
drome, a cluster of biochemical and physiological abnorm-
alities associated with the development of cardiovascular
disease and type 2 diabetes, which is commonly found in
women with PCOS.12 Excess weight and inactivity inde-
pendently increase the severity of insulin resistance,10,62,72
and women with PCOS report excess weight as a major
source of concern and stress.73 .72,74
Researchers have made a connection between weight
cycling, inﬂammation, and higher insulin levels. High
levels of insulin have been shown to cause low blood
sugar, which at times can lead to an appetite stimulant
and strong cravings for carbohydrates.34,67 The body
craves carbohydrates as a physiological need to raise
blood sugar to normal levels.36,62,75A few studies have
found that even a single day of high-fat overfeeding was
enough to impair glycemic control and reduce insulin
sensitivity in healthy adults.76,77 These ﬁndings are sig-
niﬁcant for PCOS patients experiencing binge eating, since
they suggest that severe binge eating behaviors may have
instantaneous metabolic health consequences for the
individual.
These ﬁndings have implications for binge eating in
PCOS. Altered insulin levels may contribute to weight
gain, which is associated with increased distress regarding
weight status, initiating the dieting cycle: starting a diet,
staying on it for a while with some weight loss, however
dietary restraint promotes disinhibition and overeating,
leading to binge eating and long-term weight gain through
various metabolic and dietary processes, and the cycle
repeats.20,23,74 However, further research is needed to
assess the underlying mechanisms of how insulin may be
implicated in the etiology of binge eating and PCOS.76,77
Psychological factors
Many women with PCOS experience symptoms such as
acne, hair loss, excessive hair growth, weight gain, which
may impact negatively on body image, and subsequently
contribute to binge eating behaviors.19,37 Research has
shown that high levels of body dissatisfaction with self-
appearance and physical characteristics are prevalent in
women with PCOS (eg,37,78). Further, considerable evi-
dence suggests that high levels of body dissatisfaction
confer risk for engaging in disordered eating.79 For these
reasons, individuals with high levels of body dissatisfac-
tion may predispose individuals to overeat or engage in
restrictive eating, in an attempt to cope with the psycho-
social stressors associated with PCOS symptoms. Such
behaviors may lead to clinically signiﬁcant disordered
eating, such as taking laxatives and diet pills, fasting,
engaging in excessive exercise, and induced vomiting;
culminating in the development of an ED. Moreover,
women with PCOS, because of their hormonal imbalances,
may be more prone to mood disturbances.19,80
Accordingly, recent meta-analyses have revealed an
increased prevalence of depression and anxiety associated
with PCOS compared with controls.6,16 This is signiﬁcant
as negative emotions are a key driver for binge eating
behavior, therefore experiencing negative emotions may
predispose individuals to engage in disordered eating
behaviors to regulate emotions.39 Lee and colleagues8
results demonstrated that increased ratings of depression
and anxiety were related to a higher probability of also
presenting with eating pathology and this relationship
remained signiﬁcant even after controlling for age and
BMI. Another, large population-based study from
Sweden reported an increased probability of PCOS
women experiencing BN symptoms, even after controlling
for other psychiatric disorders.18 The overrepresentation of
ED pathology in PCOS populations may be in part
explained by the high levels of body dissatisfaction, and
increased prevalence of mood and anxiety disorders,
which are both independently associated with disordered
eating.37,39
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Management of PCOS and binge
eating
Early and reliable identiﬁcation of binge eating symptoms
in PCOS populations is essential for optimal psychological
and physical outcomes for women living with PCOS.32
However, research has shown that both PCOS and ED
diagnoses are often delayed, involve numerous health pro-
fessionals, and leave women with unmet information
needs.73,81 Some women describe this time of uncertainty
as a physical and “emotional roller-coaster ride”.73
A timely diagnosis of both disorders is therefore important
to promote lifestyle management early on to prevent
weight gain, obesity, and related metabolic complications.
The Androgen Excess-PCOS society guidelines from
201832 acknowledge the clinical signiﬁcance of this issue
and advocate for the screening of disordered eating in all
women with PCOS. Screening during routine visits can be
time-consuming, but measures such as the SCOFF,82 com-
prised of only ﬁve questions, could be employed to screen
for EDs in routine practice. Furthermore, it is important to
raise awareness and provide education to women about
disordered eating in PCOS, as many women with EDs are
undiagnosed and unaware that their eating and weight-
related thoughts and behaviors are unusual and result in
distress.83
Addressing the comorbidity of PCOS and EDs pro-
vides an exceptional and difﬁcult dilemma of trying to
achieve sometimes conﬂicting goals of weight loss and
psychological well-being. Lifestyle modiﬁcation is the
cornerstone of treatment for PCOS women; however,
hormonal medication such as insulin sensitizing agents
are useful and effective adjuncts to therapy.32 Taking
a more ﬂexible approach to weight management in
women with both PCOS and ED would be optimal in
order to prevent accomplishing a “healthy” weight at the
cost of quality of psychological well-being. This should
ideally be done through a collaborative multidisciplinary
effort of numerous health care professionals, including
dieticians, mental health professionals, endocrinologists,
gynecologists, and primary healthcare providers. It would
be important to monitor the PCOS women’s diet to help
with the symptoms that result from an excess of andro-
gens and insulin resistance, to decrease the risk of dia-
betes and heart disease later in life. Research has shown
that women suffering from PCOS and comorbid mood
disorders, beneﬁted more in terms of weight management
when undergoing cognitive behavioral therapy (CBT)
along with lifestyle changes, than from lifestyle changes
alone.84 Research has also shown that CBT85 and
mindfulness86 interventions are helpful in reducing food
cravings for individuals with BED. However, these treat-
ments have not yet been assessed in PCOS women with
comorbid eating pathology, but it is likely that approach-
ing weight management in a way that also tackles the
principal psychological mechanisms of EDs, would be
more promising than only approaching weight manage-
ment alone.
Conclusions
To conclude, the current review has shown that women
with PCOS have elevated prevalence and risk factors for
binge eating behavior, such as overweight and/or obesity,
negative body image, depression and anxiety37,80 The
suggested links between PCOS and binge eating are not
yet well understood,67 but it is likely that they may include
metabolic (hyperandrogenism), hormonal (insulin resis-
tance), and psychological (body dissatisfaction, depres-
sion, anxiety) factors. The interaction of these factors
likely is complex in nature. Further research is therefore
required to disentangle the intricacies of the relationships
between these factors to better comprehend the long-term
health risks related to the comorbidity of PCOS and binge
eating behaviors. This may be most appropriately achieved
through longitudinal studies. Screening PCOS women for
binge eating symptoms, and recognition of the life-course
implications of the comorbidity of PCOS and binge eating
is essential. Identiﬁcation of the early signs and symptoms
for both disorders and collaborative management from
patients and health professionals is required to effectively
manage PCOS and EDs, and prevent the complications
resulting from both disorders. Considering the current
array of treatments available for women with PCOS and
binge eating, more studies observing the effect of com-
bined treatments for both disorders would be beneﬁcial.
The successful management and treatment of PCOS and
binge eating behaviors rely on both conditions being
addressed in a holistic manner, which ensures all aspects
of women with PCOS’ functioning are considered prior to
the implementation of treatment.
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